Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $156 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $41 | $56 | $55 | $156 |
| Gross Profit | -$41 | -$56 | -$55 | -$54 |
| % Margin | – | – | – | -34.4% |
| R&D Expenses | $1,621 | $3,767 | $2,127 | $2,915 |
| G&A Expenses | $7,167 | $4,792 | $5,388 | $8,136 |
| SG&A Expenses | $7,167 | $4,792 | $5,388 | $8,136 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$41 | $2,702 | $2,525 | $0 |
| Operating Expenses | $8,747 | $11,261 | $10,040 | $11,050 |
| Operating Income | -$8,788 | -$11,261 | -$10,040 | -$11,050 |
| % Margin | – | – | – | -7,087% |
| Other Income/Exp. Net | -$152 | $13 | $23 | $117 |
| Pre-Tax Income | -$8,940 | -$11,247 | -$10,017 | -$10,933 |
| Tax Expense | $264 | $264 | $264 | $144 |
| Net Income | -$8,790 | -$10,917 | -$9,768 | -$10,790 |
| % Margin | – | – | – | -6,920.1% |
| EPS | -0.8 | -1.27 | -1.3 | -1.59 |
| % Growth | 37% | 2.3% | 18.2% | – |
| EPS Diluted | -0.8 | -1.27 | -1.3 | -1.7 |
| Weighted Avg Shares Out | 11,007 | 11,590 | 11,590 | 11,590 |
| Weighted Avg Shares Out Dil | 11,007 | 11,590 | 11,590 | 11,590 |
| Supplemental Information | – | – | – | – |
| Interest Income | $21 | $13 | $23 | $117 |
| Interest Expense | $172 | $0 | $0 | $0 |
| Depreciation & Amortization | $41 | $56 | $55 | $54 |
| EBITDA | -$8,726 | -$11,191 | -$9,985 | -$10,997 |
| % Margin | – | – | – | -7,052.6% |